Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
Rhea-AI Summary
Vivos Therapeutics (NASDAQ: VVOS) closed a private placement with New Seneca affiliate V-Co 3, raising $2.25 million (includes conversion of a prior $1.4 million bridge note) on March 31, 2026. Vivos issued common stock, a pre-funded warrant, and 2- and 5-year warrants exercisable at $1.09.
V-Co 3 paid $1.34 per share/warrant; aggregate Seneca investments since 2024 total $13.4 million. Vivos recorded an original issue discount of $140,000 and intends to use net proceeds for general working capital while pursuing its medical affiliation model and breakeven cash flow goal by end of 2026.
Positive
- Gross proceeds of $2.25 million closed March 31, 2026
- Seneca affiliates have invested an aggregate of $13.4 million since 2024
- Company pursuing medical affiliation model with recent in-network and Medicare participation wins
Negative
- Private placement includes pre-funded warrant and multiple warrants, creating potential dilution
- Warrants exercisable at $1.09 and shares sold at $1.34, indicating potential near-term dilution pressure
- Original issue discount of $140,000 was recorded related to prior bridge funding
News Market Reaction – VVOS
On the day this news was published, VVOS declined 5.34%, reflecting a notable negative market reaction. Argus tracked a trough of -3.3% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $774K from the company's valuation, bringing the market cap to $13.71M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VVOS was down 0.76% while momentum peers like IINN and COCH showed upside moves, and other close peers posted mixed performance. This points to a largely stock-specific reaction to the private placement rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Insurance access update | Positive | +4.4% | Nevada practices gained insurer in-network and Medicare participating status with cost cuts. |
| Mar 17 | Clinical study highlight | Positive | +1.5% | Peer-reviewed study supported anatomical link to OSA and referenced Vivos’ 510(k) clearance. |
| Feb 05 | Commercial collaboration | Positive | +0.0% | Collaboration with SoundHealth to distribute FDA-cleared devices and tech across network. |
| Feb 05 | Warrant proceeds closed | Negative | -7.1% | Closing of reduced-price warrant exercise for $4.64M gross with new warrants issued. |
| Jan 16 | Warrant exercise deal | Negative | -3.3% | Deal for immediate warrant exercise at reduced price and issuance of new investor warrants. |
Capital-raising events have previously triggered negative price moves, while strategic and operational updates have tended to align with modestly positive or flat reactions.
Over recent months, Vivos has combined strategic partnerships, operational shifts, and repeated capital-raising steps. In January 2026, warrant exercises and inducement structures raised about $4.64 million, followed by a collaboration with SoundHealth to broaden device and diagnostic capabilities. March updates highlighted clinical validation of its OSA approach and insurer and Medicare access gains in Nevada, supporting the medical affiliation pivot. Those operational positives saw modestly positive or flat price reactions, while financing-related news showed more pronounced downside, framing today’s private placement within an ongoing balance between funding needs and growth execution.
Regulatory & Risk Context
An effective S-3 resale registration covers 3,964,712 warrant shares at $2.09 per share, with the company eligible to receive up to $8.29 million in cash if all are exercised, while selling holders may resell shares over time.
Market Pulse Summary
The stock moved -5.3% in the session following this news. A negative reaction despite fresh funding would fit past patterns where capital-raising steps coincided with weakness even when proceeds strengthened liquidity. This private placement brings $2.25 million in gross proceeds and converts a $1.4 million bridge note but also adds more warrants on top of an existing S-3 resale registration. In that context, concerns about dilution and the stock trading below its 200-day MA could outweigh the strategic support from the lead investor.
Key Terms
private placement financial
pre-funded warrant financial
common stock purchase warrant financial
original issue discount financial
Nasdaq Stock Market LLC financial
Form 8-K regulatory
AI-generated analysis. Not financial advice.
Private Placement Funds Operations as Vivos’ Medical Affiliation Model Begins to Take Hold
LITTLETON, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), announced that it has closed on a private placement with V-Co Investors 3 LLC (“V-Co 3”), an affiliate of New Seneca Partners Inc. (“Seneca”). Gross proceeds of
This new investment demonstrates support by Seneca of Vivos’ emerging medical affiliation distribution model, highlighted by Vivos’ 2025 acquisition of the operating assets of The Sleep Center of Nevada and recent wins such as Vivos’ announcement that physician-owned professional entities supported by its wholly-owned management services subsidiary in Nevada have received notices of ‘in-network’ status with a number of commercial health insurance payers, along with ‘participating’ status with Medicare.
Since 2024, affiliates of Seneca have invested an aggregate of
In the most recent private placement, Vivos sold to V-Co 3 common stock, a pre-funded warrant to purchase shares of common stock, a 2-year common stock purchase warrant, and a 5-year common stock purchase warrant, both exercisable at
Vivos intends to use the net proceeds from the private placement for general working capital purposes.
Michael Skaff, Managing Director of New Seneca Partners, stated “Seneca has been in lockstep with Vivos management as they have executed on their strategic pivot toward affiliations with and acquisitions of sleep and cardiology medicine practices and sleep testing centers as a means of offering comprehensive OSA diagnostic services and driving sales of Vivos’ proprietary OSA treatment devices. Vivos is focused on executing on key immediate term initiatives, including optimizing its operations in Las Vegas and Detroit, onboarding large new practice relationships, closely managing expenses (particularly those related to its legacy, dentist-focused business model) and rolling out additional diagnostic procedures, all of which support Vivos’ goal of achieving breakeven operating cash flow by the end of 2026. Our third follow-on equity investment reflects our significant enthusiasm and commitment to what Vivos is doing and the potential within their new model. Seneca and its affiliates have been long-term investors and believe Vivos is significantly undervalued.”
Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, stated “We’re very grateful to Seneca for their support and faith in our business model and prospects. We continue to optimize our new model in Las Vegas and elsewhere, cut costs, and explore strategies to drive revenue and get our groundbreaking OSA treatments into the hands of more patients. We look forward to continuing our work on behalf of these OSA patients and all of our shareholders and stakeholders.”
Additional details regarding the private placement were disclosed by Vivos in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on April 3, 2026.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.
OSA affects over 1 billion people worldwide, yet
Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.
Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, including statements of the Company’s management and other parties made in connection therewith, contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “would”, “should”, “expects”, “projects,” “potential,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”. “aim” “is expected to,” and variations of such words and similar expressions are intended to identify forward-looking statements.
In this press release, forward-looking statements include, without limitation, those relating to the Company's goal of becoming cash flow positive.
These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to effectively market or sell products or continue to integrate business from the acquisition and alliance model into its own or otherwise implement sales, marketing, and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to continue operations, acquire additional sleep centers practices or enter into management services support affiliations on reasonable terms, or maintain its Nasdaq listing when needed, if at all, (v) the risk that actual cost savings from cost reduction initiatives may be less than estimated or may be offset by transition costs, severance obligations, or operational disruptions, (vi) the risk that in-network status may be modified, terminated, or subject to reimbursement rate changes by insurers, (vii) the risk that patient volume increases may not materialize at the pace or magnitude anticipated, (viii) market and other conditions that could impact Vivos’ business or ability to obtain financing; and (ix) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Media Inquiries:
Jennifer Hauser, Executive Assistant to the CEO
Investor Relations Contact
investors@vivoslife.com
